CN104415066A - 一种治疗退行性疾病的组合物 - Google Patents
一种治疗退行性疾病的组合物 Download PDFInfo
- Publication number
- CN104415066A CN104415066A CN201310404390.4A CN201310404390A CN104415066A CN 104415066 A CN104415066 A CN 104415066A CN 201310404390 A CN201310404390 A CN 201310404390A CN 104415066 A CN104415066 A CN 104415066A
- Authority
- CN
- China
- Prior art keywords
- royal jelly
- acid
- degenerative disease
- compositions
- aminobutyric acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 208000015122 neurodegenerative disease Diseases 0.000 title claims abstract description 33
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 76
- QHBZHVUGQROELI-SOFGYWHQSA-N (E)-10-hydroxydec-2-enoic acid Chemical compound OCCCCCCC\C=C\C(O)=O QHBZHVUGQROELI-SOFGYWHQSA-N 0.000 claims abstract description 68
- QHBZHVUGQROELI-UHFFFAOYSA-N Royal Jelly acid Natural products OCCCCCCCC=CC(O)=O QHBZHVUGQROELI-UHFFFAOYSA-N 0.000 claims abstract description 66
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 42
- 241000218628 Ginkgo Species 0.000 claims abstract description 41
- 235000011201 Ginkgo Nutrition 0.000 claims abstract description 41
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims abstract description 29
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 29
- 239000003814 drug Substances 0.000 claims abstract description 8
- 241001597008 Nomeidae Species 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 6
- 229910052751 metal Inorganic materials 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 4
- 239000000945 filler Substances 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 229910021529 ammonia Inorganic materials 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 239000012752 auxiliary agent Substances 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- -1 dimethyl sulfoxine Chemical compound 0.000 claims description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000008157 edible vegetable oil Substances 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 229940109850 royal jelly Drugs 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000011573 trace mineral Substances 0.000 claims description 2
- 235000013619 trace mineral Nutrition 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- 239000011701 zinc Substances 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- 230000015654 memory Effects 0.000 abstract description 12
- 210000004556 brain Anatomy 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 10
- 230000006870 function Effects 0.000 abstract description 8
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 230000036285 pathological change Effects 0.000 abstract description 4
- 231100000915 pathological change Toxicity 0.000 abstract description 4
- 230000028327 secretion Effects 0.000 abstract description 4
- 238000003786 synthesis reaction Methods 0.000 abstract description 4
- 230000036770 blood supply Effects 0.000 abstract description 3
- 230000007547 defect Effects 0.000 abstract description 3
- 230000037356 lipid metabolism Effects 0.000 abstract description 3
- 208000010877 cognitive disease Diseases 0.000 abstract description 2
- 230000006866 deterioration Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 description 17
- 210000002569 neuron Anatomy 0.000 description 10
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 5
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 5
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 5
- 230000002490 cerebral effect Effects 0.000 description 5
- 229930003944 flavone Natural products 0.000 description 5
- 150000002212 flavone derivatives Chemical class 0.000 description 5
- 235000011949 flavones Nutrition 0.000 description 5
- 150000002596 lactones Chemical class 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 5
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 4
- MOLPUWBMSBJXER-YDGSQGCISA-N bilobalide Chemical compound O([C@H]1OC2=O)C(=O)[C@H](O)[C@@]11[C@@](C(C)(C)C)(O)C[C@H]3[C@@]21CC(=O)O3 MOLPUWBMSBJXER-YDGSQGCISA-N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- XQVWKOMVRJFHFW-UHFFFAOYSA-N 4-aminobutanoic acid;calcium Chemical compound [Ca].NCCCC(O)=O XQVWKOMVRJFHFW-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000019771 cognition Effects 0.000 description 3
- 230000003920 cognitive function Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 210000004295 hippocampal neuron Anatomy 0.000 description 3
- 210000001320 hippocampus Anatomy 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000006403 short-term memory Effects 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 210000000225 synapse Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000012935 Averaging Methods 0.000 description 1
- 208000024806 Brain atrophy Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008096 Cerebral atrophy Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 241000218791 Ginkgoaceae Species 0.000 description 1
- 102000008214 Glutamate decarboxylase Human genes 0.000 description 1
- 108091022930 Glutamate decarboxylase Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010034719 Personality change Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001222 gaba-ergic neuron Anatomy 0.000 description 1
- 230000003371 gabaergic effect Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007087 memory ability Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 230000009223 neuronal apoptosis Effects 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000001032 spinal nerve Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Insects & Arthropods (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Animal Husbandry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
一种治疗退行性疾病的组合物,为了解决现有的药物不能逆转退行性疾病的病理变化,治疗效果不太理想的技术问题,采用的技术方案是组合物包括王浆酸或王浆酸衍生物、银杏叶,其重量份数比为(0.1~10):(1~100)。技术效果是王浆酸或王浆酸衍生物、γ-氨基丁酸或γ-氨基丁酸衍生物、银杏叶在发挥各自作用的同时能够协同增效,显著增加其整体功能,有效改善老年人因机体退化引起的脂类代谢,弥补体内合成分泌不足的缺陷,增加脑供血量,达到有效治疗和延缓退行性疾病进展、改善患者记忆和认知功能障碍的效果,大大提高了退行性疾病患者的生活质量(P<0.01)。
Description
技术领域
本发明属于医药制品技术领域,涉及到一种组合物,特别是一种治疗退行性疾病的组合物。
背景技术
退行性疾病是一种大脑和脊髓的细胞神经元丧失的疾病状态。大脑和脊髓由神经元组成,神经元有不同的功能,如控制运动,处理感觉信息,并作出决策。大脑和脊髓的细胞一般是不会再生的,所以过度的损害可能是毁灭性的,不可逆转的。退行性疾病是由神经元或其髓鞘的丧失所致,随着时间的推移而恶化,导致功能障碍。退行性疾病包括阿尔兹海默氏病(AD)、肌肉萎缩性侧索硬化症、帕金森病、小脑萎缩症、亨廷顿氏病、克雅二氏病、多发性硬化症等,其中,阿尔兹海默氏病(AD)又叫老年性痴呆,是一种与年龄高度关联的中枢神经系统变性病,主要表现为渐进性记忆障碍、认知功能障碍、人格改变及语言障碍等神经精神症状,严重影响社交、职业与生活功能。其主要病理解剖基础是脑萎缩,在认知和记忆的相关区域,如前脑基底和海马区尤为明显,病因是神经元细胞内神经原纤维缠结和细胞外淀粉样斑的形成,细胞外淀粉样斑主要由β-淀粉样蛋白(Aβ)所引起,β-淀粉样蛋白(Aβ)异常分泌和产生过多,在脑组织内沉积,对周围的突触和神经元具有毒性作用,可破坏突触膜,导致神经元数目减少、神经细胞再生能力下降、神经递质乙酰胆碱(Ach)含量减少、胆碱能神经兴奋传递产生障碍,最终引起神经细胞死亡,是阿尔兹海默氏病(AD)发生、发展的中心环节。神经原纤维缠结是由于Tau蛋白异常过度磷酸化形成病理性沉积所造成的。
流行病学研究表明,在65岁左右的老人中,阿尔兹海默氏病(AD)的发病率为2~5%,随着年龄增长,发病率也相应提高,80岁以上增加到15~20%。阿尔兹海默氏病(AD)是继心血管疾病、癌症和脑卒中之后,引起老人死亡的第四大病因。
目前临床尚无药物能够逆转退行性疾病的病理变化,而且目前针对退行性疾病患者的药物往往均有不同程度的毒副作用,治疗效果不太理想。
发明内容
本发明的目的是为了解决现有的药物不能逆转退行性疾病的病理变化,治疗效果不太理想的技术问题,为了解决这个问题,我们设计了一种治疗退行性疾病的组合物,可以显著增加其整体功能,改善老年人因机体退化引起的脂类代谢,弥补体内合成分泌不足的缺陷,有效逆转退行性疾病的病理变化,达到治疗和延缓退行性疾病进展、改善患者记忆和认知功能障碍的效果,可提高注意力和短时记忆等认知功能,显著改善退行性疾病患者的症状,大大提高了患者的生活质量(P<0.01)。
本发明所采用的具体技术方案是:一种治疗退行性疾病的组合物,关键是:所述的组合物包括王浆酸或王浆酸衍生物、银杏叶,其重量份数比为(0.1~10):(1~100)。
本发明的有益效果是:王浆酸或王浆酸衍生物、γ-氨基丁酸或γ-氨基丁酸衍生物、银杏叶在发挥各自作用的同时能够协同增效,可以显著增加其整体功能,有效改善患者因机体退化引起的脂类代谢,弥补体内合成分泌不足的缺陷,显著改善退行性疾病患者的症状,增加脑供血量,有效抑制神经细胞死亡,达到治疗和延缓退行性疾病进展、改善患者记忆和认知功能障碍的效果,可提高注意力和短时记忆等认知功能,大大提高了患者的生活质量(P<0.01)。组合物可制成片剂、或胶囊、或液剂、或粉剂供患者选择,方便实用。
王浆酸的天然物仅存在于蜂王浆中,是蜂王浆标志性成分。王浆酸可以通过由蜂王浆中提取或人工合成等方法得到,王浆酸外观为白色结晶性粉末,熔点64℃,易溶于醇,难溶于水,存放性质稳定,急毒LD50≥15600mg/kg。王浆酸在0.5~2μmol/L浓度时能够明显促进海马神经细胞的存活和增殖以及神经元细胞的增殖,神经元细胞的增殖率达18~20%,使中枢神经突触在变化中达到长时程增强(LTP),具有增强学习和记忆能力的功效。王浆酸还能影响γ-氨基丁酸能神经元形态和功能的分化,刺激轴突生长和表达谷氨酸脱羧酶。王浆酸还有胰岛素样生长因子(IGF-1)的作用,可调节神经细胞的生长、发育和分化,能抑制多种因素导致的神经细胞凋亡,促进β-淀粉样蛋白(Aβ)转运出血脑屏障而加速β-淀粉样蛋白(Aβ)的清除。王浆酸单独使用能明显改善退行性疾病患者的症状,提高退行性疾病患者的生活质量(P<0.05)。
γ-氨基丁酸是人脑中不可缺少的物质,可由人工合成、米胚芽提取等方法得到,外观为白色结晶性粉末,易溶于水微溶于乙醇,熔点195℃(分解),存放性质稳定,急毒LD50≥5400mg/kg。γ-氨基丁酸能激活脑内葡萄糖代谢,促进胆碱能神经递质乙酰胆碱(Ach)的合成,具有增强记忆的健脑作用。还可以支配脑血管,调节脑循环,扩张血管增加血流量,降低血氨,使脑细胞活动旺盛,促进脑组织的新陈代谢和恢复脑细胞功能。
银杏叶是银杏科植物银杏的叶,可有效清除自由基,并能降低β-淀粉样蛋白(Aβ)诱导NO的细胞毒性,保护神经细胞,提高注意力和短时记忆等认知功能。银杏内酯有抗炎和保护神经作用,对缺血、代谢紊乱等引起的耳聋、耳鸣有明显的改善作用,可增加脑供血量,增加海马区毒蕈碱受体密度,对老年性的脑功能紊乱、脑功能不全、失眠症、记忆损害均有明显的改善作用,一定程度上可阻止退行性疾病的进展。银杏叶中的白果内酯占2.6~3.2%,可促进神经细胞增殖,防止脑、脊髓神经脱鞘。
附图说明
图1为MTT法检测王浆酸或王浆酸衍生物、γ-氨基丁酸或γ-氨基丁酸衍生物、银杏叶按照单独或不同比例对海马神经细胞进行培养的实验数据示意图。
具体实施方式
一种治疗退行性疾病的组合物,关键是:所述的组合物包括王浆酸或王浆酸衍生物、银杏叶,其重量份数比为(0.1~10):(1~100)。
所述的组合物还包括γ-氨基丁酸或γ-氨基丁酸衍生物,王浆酸或王浆酸衍生物、γ-氨基丁酸或γ-氨基丁酸衍生物、银杏叶的重量份数比为(0.1~10):(0~50):(1~100)。
所述的王浆酸或王浆酸衍生物、银杏叶的最佳重量份数比为(1~5):(2.5~25)。
所述的王浆酸或王浆酸衍生物、γ-氨基丁酸或γ-氨基丁酸衍生物、银杏叶的最佳重量份数比为(1~5):(2~10):(2.5~25)。
所述的组合物还包括辅料,王浆酸或王浆酸衍生物、γ-氨基丁酸或γ-氨基丁酸衍生物、银杏叶、辅料的重量份数比为(0.1~10):(0~50):(1~100):(2~25)。
所述的辅料包括中药、维生素、微量元素、溶剂、助剂、填充剂、粘结剂、甜味剂、着色剂,中药为泽泻、山楂中的任意一种,溶剂为水、乙醇、二甲亚砜中的任意一种,填充剂为滑石粉、淀粉、食用油中的任意一种。
所述的王浆酸衍生物包括王浆酸与金属元素生成的王浆酸盐、与氨或胺生成的王浆酸酰胺衍生物,γ-氨基丁酸衍生物包括γ-氨基丁酸与金属元素生成的γ-氨基丁酸盐,及与王浆酸反应得到的盐、或酯或酰胺。
所述的金属元素包括钙、铁、锌。
所述的组合物的剂型为片剂、或胶囊、或液剂、或粉剂。
我们研究了王浆酸或王浆酸衍生物、γ-氨基丁酸或γ-氨基丁酸衍生物、银杏叶按照单独或不同比例对大鼠的海马神经细胞进行培养,用MTT法检测神经细胞存活的实验,实验数据如表1和图1所示。
表1
由表1和图1可知,王浆酸或王浆酸衍生物、γ-氨基丁酸或γ-氨基丁酸衍生物、银杏叶的组合物对促进大鼠海马神经细胞增殖的效果明显优于其它各组,与γ-氨基丁酸或γ-氨基丁酸衍生物相比P<0.01,与王浆酸或王浆酸衍生物、银杏叶单独使用时相比,P<0.05,与王浆酸或王浆酸衍生物、银杏叶的混合物相比,P<0.05。
下面给出本发明的具体实施例:
实施例1、按王浆酸:γ-氨基丁酸:银杏叶=2:1:2的比例将王浆酸、γ-氨基丁酸、银杏叶称量准确,充分混合后,装入硬胶囊,每粒装200mg,其中每粒含王浆酸≥75mg、γ-氨基丁酸≥38mg、银杏叶黄酮类≥17.5mg、银杏叶内酯类≥4.0mg。
实施例2、按王浆酸:γ-氨基丁酸:银杏叶=1:1:3的比例将王浆酸、γ-氨基丁酸、银杏叶称量准确,充分混合后,装入硬胶囊,每粒装250mg,其中每粒含王浆酸≥45mg、γ-氨基丁酸≥45mg、银杏叶黄酮类≥35mg、银杏叶内酯类≥8mg。
实施例3、按王浆酸亚铁:γ-氨基丁酸钙:银杏叶:淀粉=6:5:30:9的比例将王浆酸亚铁、γ-氨基丁酸钙、银杏叶、淀粉称量准确,充分混合后,制成片剂,每片250mg,其中每片含王浆酸≥50mg、γ-氨基丁酸≥40mg、银杏叶黄酮类≥3mg、银杏叶内酯类≥0.6mg。
实施例4、按王浆酸:γ-氨基丁酸:银杏叶=3:2:20的比例将王浆酸、γ-氨基丁酸、银杏叶称量准确,充分混合后,制成粉剂,每袋装2.5g,其中每袋含王浆酸≥180mg、γ-氨基丁酸≥125mg、银杏叶黄酮类≥35mg、银杏叶内酯类≥6mg。
实施例5、按王浆酸:γ-氨基丁酸钙:银杏叶:水=1:2:5:10的比例将王浆酸、γ-氨基丁酸、银杏叶、水称量准确,充分混合后制成液剂,每袋装2.5g,其中每袋含王浆酸≥100mg、γ-氨基丁酸≥70mg、银杏叶黄酮类≥20mg、银杏叶内酯类≥3mg。
将实施例1中制备的组合物分别给35名阿尔兹海默氏病(AD)患者服用,服用量为每日1次,每次1粒,服用时间15天,服用前后对其记忆力和计算力进行检查,记忆力检查采用数字广度测验法,包括顺行记忆和逆行记忆,顺行记忆读6位随机数字,逆行记忆读4位随机数字。计算力检查采用由100连续减3,看能正确减多少次,以上检查均进行3次取平均值。检查结果:明显改善26人,改善8人,无明显变化1人,有效率达97%。表明本发明能有效治疗和延缓阿尔兹海默氏病(AD)的进展、改善阿尔兹海默氏病(AD)患者的记忆和认知功能障碍。
Claims (9)
1.一种治疗退行性疾病的组合物,其特征在于:所述的组合物包括王浆酸或王浆酸衍生物、银杏叶,其重量份数比为(0.1~10):(1~100)。
2.根据权利要求1所述的一种治疗退行性疾病的组合物,其特征在于:所述的组合物还包括γ-氨基丁酸或γ-氨基丁酸衍生物,王浆酸或王浆酸衍生物、γ-氨基丁酸或γ-氨基丁酸衍生物、银杏叶的重量份数比为(0.1~10):(0~50):(1~100)。
3.根据权利要求1所述的一种治疗退行性疾病的组合物,其特征在于:所述的王浆酸或王浆酸衍生物、银杏叶的最佳重量份数比为(1~5):(2.5~25)。
4.根据权利要求2所述的一种治疗退行性疾病的组合物,其特征在于:所述的王浆酸或王浆酸衍生物、γ-氨基丁酸或γ-氨基丁酸衍生物、银杏叶的最佳重量份数比为(1~5):(2~10):(2.5~25)。
5.根据权利要求2所述的一种治疗退行性疾病的组合物,其特征在于:所述的组合物还包括辅料,王浆酸或王浆酸衍生物、γ-氨基丁酸或γ-氨基丁酸衍生物、银杏叶、辅料的重量份数比为(0.1~10):(0~50):(1~100):(2~25)。
6.根据权利要求5所述的一种治疗退行性疾病的组合物,其特征在于:所述的辅料包括中药、维生素、微量元素、溶剂、助剂、填充剂、粘结剂、甜味剂、着色剂,中药为泽泻、山楂中的任意一种,溶剂为水、乙醇、二甲亚砜中的任意一种,填充剂为滑石粉、淀粉、食用油中的任意一种。
7.根据权利要求2所述的一种治疗退行性疾病的组合物,其特征在于:所述的王浆酸衍生物包括王浆酸与金属元素生成的王浆酸盐、与氨或胺生成的王浆酸酰胺衍生物,γ-氨基丁酸衍生物包括γ-氨基丁酸与金属元素生成的γ-氨基丁酸盐,及与王浆酸反应得到的盐、或酯或酰胺。
8.根据权利要求7所述的一种治疗退行性疾病的组合物,其特征在于:所述的金属元素包括钙、铁、锌。
9.根据权利要求1所述的一种治疗退行性疾病的组合物,其特征在于:所述的组合物的剂型为片剂、或胶囊、或液剂、或粉剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310404390.4A CN104415066A (zh) | 2013-09-09 | 2013-09-09 | 一种治疗退行性疾病的组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310404390.4A CN104415066A (zh) | 2013-09-09 | 2013-09-09 | 一种治疗退行性疾病的组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104415066A true CN104415066A (zh) | 2015-03-18 |
Family
ID=52965890
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310404390.4A Pending CN104415066A (zh) | 2013-09-09 | 2013-09-09 | 一种治疗退行性疾病的组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104415066A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108175808A (zh) * | 2018-01-19 | 2018-06-19 | 北京知蜂堂健康科技股份有限公司 | 一种药物组合物及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101253984A (zh) * | 2008-03-20 | 2008-09-03 | 青岛大学医学院附属医院 | 蜂王浆银杏叶营养保健品及其制备方法 |
CN101322555A (zh) * | 2008-06-17 | 2008-12-17 | 苟春虎 | 藏药艾力壮元胶囊 |
CN101632785A (zh) * | 2008-07-25 | 2010-01-27 | 王跃进 | 凉性黑人参的制备方法 |
-
2013
- 2013-09-09 CN CN201310404390.4A patent/CN104415066A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101253984A (zh) * | 2008-03-20 | 2008-09-03 | 青岛大学医学院附属医院 | 蜂王浆银杏叶营养保健品及其制备方法 |
CN101322555A (zh) * | 2008-06-17 | 2008-12-17 | 苟春虎 | 藏药艾力壮元胶囊 |
CN101632785A (zh) * | 2008-07-25 | 2010-01-27 | 王跃进 | 凉性黑人参的制备方法 |
Non-Patent Citations (3)
Title |
---|
任非等: "银杏叶提取物治疗老年痴呆症", 《中国临床康复》 * |
沈萌: "γ-氨基丁酸的制备研究", 《中国优秀硕士学位论文全文数据库 工程科技I辑》 * |
郭芳彬: "蜂王浆与老年痴呆症", 《蜜蜂杂志》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108175808A (zh) * | 2018-01-19 | 2018-06-19 | 北京知蜂堂健康科技股份有限公司 | 一种药物组合物及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9114140B2 (en) | Integrated neuromodulation system for mood enhancement of a living human subject | |
CN105725211A (zh) | 一种用于改善睡眠的食品保健品及其制备方法 | |
EP2685998B1 (en) | Composition comprising the extract of herbs for preventing or treating neurodegenerative disorders | |
CN102920806A (zh) | 安神降压中药茶 | |
CN106174494A (zh) | 一种组合物及其在制备健脑益智的产品中的应用 | |
CN104415025A (zh) | 一种延缓退行性疾病进展的组合物 | |
CN113040393A (zh) | 一种干预焦虑睡眠障碍的营养配方 | |
CN104435100B (zh) | 一种抗抑郁组合物 | |
CN105031525B (zh) | 一种益智健脑的中药制剂及其制备方法 | |
CN104415066A (zh) | 一种治疗退行性疾病的组合物 | |
CN103705774A (zh) | 一种具有治疗抑郁症作用的复方组合物及其制备方法与应用 | |
CN106236760A (zh) | 人参皂苷c‑k与丙戊酸或丙戊酸的盐的组合物在制备抗癫痫药物中的应用 | |
EP4017278A1 (en) | Compositions comprising a metal and l-serine, and uses thereof | |
KR20110004691A (ko) | 뇌기능 개선효과를 가지는 붉나무 추출물을 포함하는 약학조성물 및 건강식품조성물 | |
CN102379907B (zh) | 灵芝二维甲硫氨酸制剂及其生产方法 | |
CN105982921A (zh) | 一种治疗痛风的组合物及其应用 | |
RU2377009C1 (ru) | Биологически активная добавка, способствующая снижению массы тела | |
US20120269794A1 (en) | Nutraceutical composition that comprises extract of shilajit, folic acid, vitamin b12 and vitamin b6 and the use thereof for preventing and/or treating neurodegenerative diseases and/or the cognitive deterioration associated with cerebral ageing | |
CA2886011C (en) | Combination for treatment and prophylaxis of behavioral, mental, cognitive and neurologic disorders in cases of organic diseases of the central nervous system | |
KR20050092292A (ko) | 기억력 증강 효과가 있는 생약재 조성물 | |
CN101199768A (zh) | 用于治疗脑萎缩和老年痴呆症的药物组合物 | |
ITTO20070391A1 (it) | Composizione di integratore alimentare,farmaco o dispositivo medicale e suo impiego per sopprimere l'appetito, migliorare tono ed umore, con attivita antidepressiva naturale e con effetto antiastenico | |
TW202103679A (zh) | 一種落葵萃取物用於製備預防或治療神經系統疾病組合物的用途 | |
AU2000234779B2 (en) | Herbal supplement for cognitive related impairment due to estrogen loss | |
Akram et al. | Effect of Methanolic Extract of Benincasa hispida on Cognitive Function in Experimental Animals |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150318 |